Biotech | March 18, 2022
Sanofi moves forward with EUROAPI listing on Euronext Paris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Company expects strong organic growth in sales, EBITDA in 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Subscribe To Our Newsletter & Stay Updated
